Mechanisms of asthma and allergic inflammation
Computed tomographic scan–diagnosed chronic obstructive pulmonary disease–emphysema: Eotaxin-1 is associated with bronchodilator response and extent of emphysema

https://doi.org/10.1016/j.jaci.2007.08.045Get rights and content

Background

Bronchodilator responses are a hallmark of asthma and a subset of chronic obstructive pulmonary disease (COPD). We evaluated subjects with COPD and computed tomographic (CT) scan evidence of emphysema to determine the biomarker profile associated with a bronchodilator response.

Objective

We investigated whether subjects with COPD and a bronchodilator response had increased levels of bronchoalveolar lavage (BAL) fluid eosinophil biomarkers, TH2 cytokines, CC chemokines, and serum allergen-specific IgE.

Methods

All patients with COPD and control subjects (n = 31) had chest CT scans to detect emphysema and subsequent pulmonary function studies, BAL for biomarkers, and serum IgE measurements.

Results

CT scan score, FEV1, carbon monoxide single-breath diffusion capacity, and BAL fluid neutrophil biomarker levels were similar in subjects with COPD who had or did not have a bronchodilator response of greater than 12%. In contrast, levels of BAL fluid eosinophil biomarkers (eosinophil cationic protein [ECP] and eotaxin-1) were greater in patients with COPD with a bronchodilator response, whereas TH2 cytokines were not detectable in any patients with COPD. BAL fluid ECP and eotaxin-1 levels correlated with CT scan extent of emphysema. Immunostaining of COPD lung sections from a separate cohort of subjects with COPD and healthy subjects demonstrated epithelial expression of eotaxin-1 but no lung expression of IL-4 or IL-5.

Conclusion

Subjects with COPD diagnosed on the basis of the presence of emphysema on CT scan who have a bronchodilator response have increased levels of BAL ECP and eotaxin-1 but not TH2 cytokines.

Clinical implications

Eosinophil biomarkers (ECP-1 and eotaxin-1) might identify a subset of subjects with COPD with emphysema on CT scans who have a bronchodilator response and an increased extent of emphysema on CT scanning.

Section snippets

Study subjects

Subjects with COPD were recruited based on chest CT scan evidence of emphysema, pulmonary function studies, and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) clinical evaluation (history of chronic cough, sputum production, and dyspnea).10 They also completed a standardized COPD questionnaire (ie, St George Questionnaire; possible score, 0-100).11 Healthy individuals were nonsmokers who had no evidence of disease on history and physical examination and had a normal chest CT

COPD study subject CT scan results, pulmonary function test results, and clinical characteristics

The subjects with COPD (n = 16) had evidence of significant emphysema based on their chest CT scan results and FEV1 values (Fig 1). In contrast, none of the subjects in either the healthy nonsmoking group (n = 7) or the current smoker group (n = 8) had evidence of COPD on chest CT scan or abnormalities of pulmonary function (Fig 1).

Subjects with COPD-E had a significantly higher chest CT scan score (36.8% ± 4.0% voxels < −920 HU) compared with those of either the healthy nonsmoking group (3.3%

Discussion

In this study we have demonstrated that subjects with GOLD stage III moderate-to-severe COPD-E (enrolled on the basis of CT scan evidence of emphysema rather than pulmonary function testing) express a biomarker profile (ECP-1 and eotaxin-1) associated with bronchodilator responsiveness and also correlated with the extent of emphysema on CT scanning. The significant correlation between BAL fluid ECP level and the extent of emphysema on chest CT scanning raises the possibility that activated

References (20)

There are more references available in the full text version of this article.

Cited by (30)

  • Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease

    2022, Pharmacology and Therapeutics
    Citation Excerpt :

    Studies have reported increases in eosinophils in pulmonary biopsies (Pesci et al., 1998; Pesci, Majori, et al., 1998; Saetta et al., 1994) and that eosinophils are associated with a reduction of lung function in COPD patients, as evidenced by reductions in FEV1 (Pesci, Majori, et al., 1998). Moreover, people with COPD displaying chronic bronchitis and emphysema presented with increased levels of activated eosinophils in the large-airway subepithelia and broncho alveolar lavage fluid respectively (Lams, Sousa, Rees, & Lee, 2000; Miller et al., 2007). Therefore, eosinophils could potentially be contributing to obstructive phenotypes observed in patients with COPD.

  • Eosinophils in COPD: just another biomarker?

    2017, The Lancet Respiratory Medicine
  • Are asthma and COPD a continuum of the same disease?

    2015, Journal of Allergy and Clinical Immunology: In Practice
  • The role of CT scanning in multidimensional phenotyping of COPD

    2011, Chest
    Citation Excerpt :

    However, these differences could be accounted for by differences in study design. Interestingly, Miller and colleagues42 found close correlations between eosinophil degradation products and EM score in a group of well-characterized patients with COPD, suggesting that these may contribute to the progression of EM. In this study, we have shown that FEV1 using regression model analysis was not predictive for the identification of EM, BE, or BWT on CT scan.

  • Persistent airway inflammation and emphysema progression on CT scan in ex-smokers observed for 4 years

    2011, Chest
    Citation Excerpt :

    In brief, subjects with COPD-E were recruited based on clinical evaluation and chest CT scan evidence of emphysema, which had to be present to be included in the study, whereas control subjects were required to have no clinical evidence of COPD and a normal chest CT scan.16 Subjects also completed pulmonary function studies, clinical evaluation (history of chronic cough, sputum production, dyspnea), and a standardized COPD questionnaire (ie, St. George Questionnaire).16 The COPD-E cohort (n = 10) we enrolled was composed of subjects with GOLD (Global Initiative for Chronic Lung Disease) stage IIb moderately severe COPD (FEV1 30%-50%), with chest CT scan evidence of significant emphysema.16

  • Biomarkers in COPD

    2010, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Levels of eosinophil cationic protein (ECP), myeloperoxidase, and IL-8 are frequently increased in patients with COPD and in healthy smokers compared with healthy non-smokers, an observation suggesting that smoking, rather COPD itself, induces the changes [3]. It has been reported that BAL neutrophil markers [49], and both BAL and epithelial cell CD8+ T cell numbers [46] were inversely associated with FEV1, while ECP and eotaxin-1 levels were positively associated with bronchodilator response and the extent of radiographic emphysema [50]. Recently, it has been documented that in the BAL fluid compartment of COPD patients, the total recovered lipid metabolite amount, particularly prostaglandin D2 and eicosapentaenoic acid show a remarkable linear correlation with lung function [51].

View all citing articles on Scopus

Supported by National Institutes of Health grants HL72342 and GCRC MO1RR000827.

Disclosure of potential conflict of interest: M. Miller, J. Ramsdell, P. J. Friedman, J. Y. Cho, M. Renvall, and D. H. Broide have received grant support from the National Institutes of Health.

View full text